FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200048265> ?p ?o ?g. }

• W4200048265 abstract "Introduction: The ATR (ataxia-telangiectasia and Rad3 related protein) kinase inhibitor BAY 1895344 is currently in clinical development for the treatment of advanced solid tumors and has demonstrated promising antitumor activity in heavily pretreated patients with various advanced solid tumors, particularly those with <i>ATM</i> deleterious mutations and/or loss of ATM protein. There is further need to identify robust predictive biomarkers to optimize patient selection for ATR inhibitors. For that purpose, we tested the antitumor activity of BAY 1895344 in patient-derived xenograft (PDX) models that are characterized by a variety of DDR alterations. Methods: PDX models were characterized by genomic sequencing and ATM loss by immunohistochemistry (IHC). PDX models with deleterious <i>ATM</i>, <i>BRCA1</i> or <i>BRCA2</i> mutations or loss derived from a variety of histologies were tested. BAY1895344 treatment was tested with two monotherapy regimens 20 mg/kg and 40 mg/kg PO BID both 3 days on/4 days off. For <i>in vivo</i> studies, the percent tumor volume change per time point was calculated as a relative level of tumor growth change from baseline: , where is the tumor volume at time and is the tumor volume at baseline. T/C ratio was defined as the ratio of tumor volume change in treated vs control group. An event in each animal was defined as a doubling of tumor volume from initial tumor volume. Event free survival was analyzed by Kaplan-Meier survival analysis. Results: Seventeen PDX models from sixteen patients were treated with BAY 1895344. The PDX models spanned multiple tumor types: breast, colon, pancreas, and cholangiocarcinoma. BAY 1895344 has shown potent and dose-dependent antitumor activity. Strongest activity was observed with BAY 1895344 at 40 mg/kg PO BID applied for 3 days on and 4 days off treatment, achieving a regression or T/C ratio <0.4 in 6 of 17 models. Eleven models showed statistically significant prolongation of event-free survival. BAY 1895344 had anti-tumor activity in PDX models with ATM loss as well as <i>BRCA</i> alterations. Notably BAY 1895344 had antitumor activity in an ATM-deleted PDX model with acquired PARP inhibitor resistance generated in the lab as well as a PDX model generated from a <i>BRCA</i>-mutant patient with clinically acquired PARP resistance. Conclusion: ATR inhibition via treatment with BAY 1895344 shows potent antitumor activity as monotherapy in selected models that are characterized by certain DDR alterations and even those that have developed resistance to PARP inhibition. Further analyses are ongoing to define predictors of sensitivity to BAY 1895344 as well as pharmacodynamic markers of efficacy/response as a single agent or in rational combinations <b>Citation Format:</b> Christian X. Cruz Pico, Dali Li, Christopher D. Lanier, Kurt Evans, Maria G. Raso, Timothy DiPeri, Yasmeen Rizvi, Min Jin Ha, Huiqin Chen, Ming Zhao, Argun Akcakanat, Xiaofeng Zheng, Gokce Toruner, Erkan Yuca, Stephen Scott, Antje M. Wengner, Timothy A. Yap, Funda Meric-Bernstam. Anti-tumor activity of ATR inhibitor BAY 1895344 in patient-derived xenograft (PDX) models with DNA damage response (DDR) pathway alterations [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2021 Oct 7-10. Philadelphia (PA): AACR; Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P058." @default.
• W4200048265 created "2021-12-31" @default.
• W4200048265 creator A5001007969 @default.
• W4200048265 creator A5002016864 @default.
• W4200048265 creator A5003352674 @default.
• W4200048265 creator A5007131126 @default.
• W4200048265 creator A5024886364 @default.
• W4200048265 creator A5025584573 @default.
• W4200048265 creator A5030069710 @default.
• W4200048265 creator A5039812679 @default.
• W4200048265 creator A5045794188 @default.
• W4200048265 creator A5050568174 @default.
• W4200048265 creator A5064749364 @default.
• W4200048265 creator A5068368047 @default.
• W4200048265 creator A5068870075 @default.
• W4200048265 creator A5073222026 @default.
• W4200048265 creator A5076426660 @default.
• W4200048265 creator A5082835384 @default.
• W4200048265 creator A5083283915 @default.
• W4200048265 creator A5090637113 @default.
• W4200048265 date "2021-12-01" @default.
• W4200048265 modified "2023-10-17" @default.
• W4200048265 title "Abstract P058: Anti-tumor activity of ATR inhibitor BAY 1895344 in patient-derived xenograft (PDX) models with DNA damage response (DDR) pathway alterations" @default.
• W4200048265 doi "https://doi.org/10.1158/1535-7163.targ-21-p058" @default.
• W4200048265 hasPublicationYear "2021" @default.
• W4200048265 type Work @default.
• W4200048265 citedByCount "0" @default.
• W4200048265 crossrefType "proceedings-article" @default.
• W4200048265 hasAuthorship W4200048265A5001007969 @default.
• W4200048265 hasAuthorship W4200048265A5002016864 @default.
• W4200048265 hasAuthorship W4200048265A5003352674 @default.
• W4200048265 hasAuthorship W4200048265A5007131126 @default.
• W4200048265 hasAuthorship W4200048265A5024886364 @default.
• W4200048265 hasAuthorship W4200048265A5025584573 @default.
• W4200048265 hasAuthorship W4200048265A5030069710 @default.
• W4200048265 hasAuthorship W4200048265A5039812679 @default.
• W4200048265 hasAuthorship W4200048265A5045794188 @default.
• W4200048265 hasAuthorship W4200048265A5050568174 @default.
• W4200048265 hasAuthorship W4200048265A5064749364 @default.
• W4200048265 hasAuthorship W4200048265A5068368047 @default.
• W4200048265 hasAuthorship W4200048265A5068870075 @default.
• W4200048265 hasAuthorship W4200048265A5073222026 @default.
• W4200048265 hasAuthorship W4200048265A5076426660 @default.
• W4200048265 hasAuthorship W4200048265A5082835384 @default.
• W4200048265 hasAuthorship W4200048265A5083283915 @default.
• W4200048265 hasAuthorship W4200048265A5090637113 @default.
• W4200048265 hasConcept C126322002 @default.
• W4200048265 hasConcept C142724271 @default.
• W4200048265 hasConcept C143425029 @default.
• W4200048265 hasConcept C143998085 @default.
• W4200048265 hasConcept C150903083 @default.
• W4200048265 hasConcept C185592680 @default.
• W4200048265 hasConcept C204232928 @default.
• W4200048265 hasConcept C207001950 @default.
• W4200048265 hasConcept C502942594 @default.
• W4200048265 hasConcept C552990157 @default.
• W4200048265 hasConcept C55493867 @default.
• W4200048265 hasConcept C71924100 @default.
• W4200048265 hasConcept C86803240 @default.
• W4200048265 hasConceptScore W4200048265C126322002 @default.
• W4200048265 hasConceptScore W4200048265C142724271 @default.
• W4200048265 hasConceptScore W4200048265C143425029 @default.
• W4200048265 hasConceptScore W4200048265C143998085 @default.
• W4200048265 hasConceptScore W4200048265C150903083 @default.
• W4200048265 hasConceptScore W4200048265C185592680 @default.
• W4200048265 hasConceptScore W4200048265C204232928 @default.
• W4200048265 hasConceptScore W4200048265C207001950 @default.
• W4200048265 hasConceptScore W4200048265C502942594 @default.
• W4200048265 hasConceptScore W4200048265C552990157 @default.
• W4200048265 hasConceptScore W4200048265C55493867 @default.
• W4200048265 hasConceptScore W4200048265C71924100 @default.
• W4200048265 hasConceptScore W4200048265C86803240 @default.
• W4200048265 hasLocation W42000482651 @default.
• W4200048265 hasOpenAccess W4200048265 @default.
• W4200048265 hasPrimaryLocation W42000482651 @default.
• W4200048265 hasRelatedWork W11854781 @default.
• W4200048265 hasRelatedWork W13350303 @default.
• W4200048265 hasRelatedWork W15417383 @default.
• W4200048265 hasRelatedWork W1592848 @default.
• W4200048265 hasRelatedWork W16805844 @default.
• W4200048265 hasRelatedWork W19647413 @default.
• W4200048265 hasRelatedWork W20538935 @default.
• W4200048265 hasRelatedWork W21399842 @default.
• W4200048265 hasRelatedWork W5016645 @default.
• W4200048265 hasRelatedWork W3419247 @default.
• W4200048265 isParatext "false" @default.
• W4200048265 isRetracted "false" @default.
• W4200048265 workType "article" @default.